JDRF and Arecor partnership to improve insulin

JDRF has announced a partnership with Arecor Ltd to support development of a stable, rapid-acting, ultra-concentrated insulin. Improved insulins would enable the miniaturization of next-generation insulin-delivery devices for people with Type 1 diabetes. The aim is to advance the pre-clinical trials of Arecor’s ultra-concentrated insulin. The ultimate goal of the partnership is to accelerate the development of a stable, rapid-acting, ultra-concentrated insulin of up to 1,000 U/mL, which will not only offer a vastly superior mealtime insulin product for people requiring less than 200 units a day, but is also a critical step towards the advancement of the miniaturization of delivery devices, including next-generation artificial pancreas systems for people with Type 1 diabetes.

This news item first appeared in Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.


Open publication

Sign me up!
Open publication
Buy a Desang kitbag